ATE326475T1 - Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten - Google Patents

Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten

Info

Publication number
ATE326475T1
ATE326475T1 AT01987135T AT01987135T ATE326475T1 AT E326475 T1 ATE326475 T1 AT E326475T1 AT 01987135 T AT01987135 T AT 01987135T AT 01987135 T AT01987135 T AT 01987135T AT E326475 T1 ATE326475 T1 AT E326475T1
Authority
AT
Austria
Prior art keywords
metal compounds
cyclic salen
caughters
antioxidants
diseases
Prior art date
Application number
AT01987135T
Other languages
English (en)
Inventor
Bernard Malfroy-Camine
Susan Doctrow
Original Assignee
Eukarion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eukarion Inc filed Critical Eukarion Inc
Application granted granted Critical
Publication of ATE326475T1 publication Critical patent/ATE326475T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01987135T 2000-11-28 2001-11-28 Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten ATE326475T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/724,776 US6589948B1 (en) 2000-11-28 2000-11-28 Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases

Publications (1)

Publication Number Publication Date
ATE326475T1 true ATE326475T1 (de) 2006-06-15

Family

ID=24911859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987135T ATE326475T1 (de) 2000-11-28 2001-11-28 Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten

Country Status (10)

Country Link
US (3) US6589948B1 (de)
EP (2) EP1688425A3 (de)
JP (1) JP4316878B2 (de)
CN (1) CN1318435C (de)
AT (1) ATE326475T1 (de)
AU (2) AU2002239381B2 (de)
CA (1) CA2430133C (de)
DE (1) DE60119784T2 (de)
RU (1) RU2003119169A (de)
WO (1) WO2002044187A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582786B2 (en) * 1992-12-07 2009-09-01 Eukarion Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US20030087455A1 (en) * 2001-11-07 2003-05-08 Eggers Mitchell D Sample carrier system
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
DE10208252A1 (de) * 2002-02-26 2003-09-04 Celanese Ventures Gmbh Konvalent fixierte Non-Metallocene, Verfahren zur Herstellung von diesen und deren Verwendung zur Polymerisation von Olefinen
US7585514B2 (en) * 2002-06-11 2009-09-08 L'oreal Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes
AU2003247144B2 (en) * 2002-08-02 2007-11-29 Mor Research Applications Ltd. Treatment of multiple sclerosis with brain targeted anti oxidant compounds
US7815894B2 (en) * 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US20060160748A1 (en) * 2003-11-25 2006-07-20 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) * 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
EP1755579A4 (de) * 2004-05-24 2009-06-10 Univ New York Verfahren zur behandlung oder prävention von pathologischen wirkungen einer akuten zunahme von hyperglykämie und/oder einer akuten zunahme von freiem fettsäurefluss
FR2875500A1 (fr) * 2004-09-21 2006-03-24 Centre Nat Rech Scient Complexe chiraux macrocycliques utilisables comme catalyseurs
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
EP2036550A4 (de) 2006-06-28 2009-07-15 Ihi Corp Arzneimittel, arzneimittelinduktionsvorrichtung, magnetdetektor und arzneimittel-designverfahren
US8252780B2 (en) * 2006-12-01 2012-08-28 Women & Infants' Hospital Organometallic complexes as therapeutic agents
US20090169484A1 (en) * 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
CN102056625B (zh) * 2008-04-04 2015-11-25 免疫之光有限责任公司 用于原位光生物调节的非侵入性系统和方法
US20090286968A1 (en) * 2008-04-25 2009-11-19 Auburn University 2-Quinoxalinol Salen Compounds and Uses Thereof
US20090298923A1 (en) * 2008-05-13 2009-12-03 Genmedica Therapeutics Sl Salicylate Conjugates Useful for Treating Metabolic Disorders
US20100209957A1 (en) * 2008-06-20 2010-08-19 Genvault Corporation Biosample storage devices and methods of use thereof
US8198322B2 (en) * 2008-06-25 2012-06-12 Board Of Regents, The University Of Texas System Apoptotic and anti-tumor activities of metallo-salens
CN102177237B (zh) * 2008-09-12 2013-10-30 金沃特公司 用于贮存和稳定生物分子的基质和介质
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN102239138A (zh) 2008-11-20 2011-11-09 株式会社Ihi 自磁性金属salen络合物
KR101050273B1 (ko) 2008-11-21 2011-07-19 세종대학교산학협력단 살렌 전이금속 착화합물, 및 그 제조 방법
WO2010106082A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
EP2729175B1 (de) 2011-07-08 2021-12-01 Duke University System zur lichtstimulation in einem medium
CN103906756B (zh) * 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
EP2580967A1 (de) * 2011-10-11 2013-04-17 Nestec S.A. Beschleunigung der Muskelerholung nach immobilisierungsinduzierter Muskelatrophie
US9937156B2 (en) 2013-10-16 2018-04-10 The Board Of Regents Of The University Of Texas System Modulation of MRTF-A activity in pathologic fibrosis and wound healing
CN105899132B (zh) 2013-12-31 2020-02-18 雅培糖尿病护理公司 自供电分析物传感器以及使用其的装置
JP6977979B2 (ja) * 2015-06-09 2021-12-08 国立大学法人大阪大学 神経損傷治療又は予防用医薬
AU2018226872A1 (en) 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
EP3642214A2 (de) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamid-ribosid-derivate und deren verwendungen
EP3654941A1 (de) 2017-07-17 2020-05-27 Keith Roizman Topische verabreichung von therapeutischen mitteln mit zellpenetrierenden peptiden zur verwendung zur behandlung von altersbedingter makuladegeneration und anderen augenerkrankungen
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
WO2019152917A1 (en) * 2018-02-02 2019-08-08 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
WO2020094789A1 (en) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and/or treating age-related hearing loss
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
WO2020237117A1 (en) * 2019-05-23 2020-11-26 Christopher Duke Compounds that react with reactive species to control byproducts
WO2020257283A1 (en) 2019-06-18 2020-12-24 Mitopower Llc Nicotinyl riboside compounds and their uses
CN115138385B (zh) * 2022-05-20 2023-03-17 四川大学 一种仿金属酶生物催化材料及其制备方法和用途
CN115869465B (zh) * 2022-12-12 2023-09-01 之江实验室 一种天然蛋白光刻胶和活性氧清除细胞支架的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106841A (en) 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
DE69026793D1 (de) * 1989-11-16 1996-06-05 Mitsui Petrochemical Ind Behälter mit einem Aufhängegriff und Verfahren zu seiner Herstellung
AU678139B2 (en) 1991-08-26 1997-05-22 Research Corporation Technologies, Inc. Method of enantio selectively epoxidizing cinnamate derivatives
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US7006677B2 (en) * 2002-04-15 2006-02-28 General Electric Company Semi-automatic segmentation algorithm for pet oncology images

Also Published As

Publication number Publication date
US7122537B2 (en) 2006-10-17
JP2004514724A (ja) 2004-05-20
EP1688425A3 (de) 2006-08-30
WO2002044187A2 (en) 2002-06-06
DE60119784D1 (de) 2006-06-22
DE60119784T2 (de) 2007-01-04
JP4316878B2 (ja) 2009-08-19
EP1688425A2 (de) 2006-08-09
CN1636007A (zh) 2005-07-06
AU2002239381B2 (en) 2007-12-13
CN1318435C (zh) 2007-05-30
AU3938102A (en) 2002-06-11
EP1349864A2 (de) 2003-10-08
WO2002044187A3 (en) 2002-09-12
US20040059107A1 (en) 2004-03-25
US6589948B1 (en) 2003-07-08
US20070123503A1 (en) 2007-05-31
CA2430133A1 (en) 2002-06-06
RU2003119169A (ru) 2004-12-10
CA2430133C (en) 2013-01-15
EP1349864B1 (de) 2006-05-17

Similar Documents

Publication Publication Date Title
ATE326475T1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0225474D0 (en) Therapeutic agents
ATE445405T1 (de) Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
GB0318447D0 (en) Therapeutic agents
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
BR0014778A (pt) Composição antimicrobiana, processos para matar bactérias, para desativar vìrus, para aperfeiçoar a saúde global de um mamìfero, para reduzir a ausência de pessoas, utilização de composição, produto antimicrobiano e conjunto de tratamento pessoal antimicrobiano
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60004504D1 (de) Tetrahydropyranderivate und deren verwendung als therapeutische mittel
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
ATE422944T1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
ATE487482T1 (de) Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen
DE60231994D1 (de) Mittel zur behandlung oder prävention allergischerg

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties